Jeffrey Edward Nelson Sells 12,245 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) COO Jeffrey Edward Nelson sold 12,245 shares of the stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $1.93, for a total transaction of $23,632.85. Following the sale, the chief operating officer directly owned 49,848 shares in the company, valued at approximately $96,206.64. The trade was a 19.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jeffrey Edward Nelson also recently made the following trade(s):

• On Monday, December 15th, Jeffrey Edward Nelson sold 58,007 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.32, for a total value of $134,576.24.

Milestone Pharmaceuticals Stock Performance

NASDAQ MIST opened at $1.89 on Friday. The stock has a market capitalization of $160.97 million, a price-to-earnings ratio of -2.30 and a beta of 0.44. The stock has a 50-day moving average of $2.23 and a 200 day moving average of $1.96. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74. Milestone Pharmaceuticals Inc. has a twelve month low of $0.63 and a twelve month high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.05. Sell-side analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Key Stories Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone announced U.S. pharmacy availability of its CARDAMYST nasal spray — a commercial launch that begins the company’s transition from development to product revenue and increases commercial visibility. Read More.
• Positive Sentiment: Zacks Research upgraded MIST from “Hold” to “Strong Buy,” which can attract short‑term buyers and momentum flows into a thinly traded microcap. Read More.
• Neutral Sentiment: Technical/trading context is mixed: shares sit below the 50‑day moving average and current volume is below the stock’s average, which may limit a sustained rally despite the launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto executed large sales (133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93). Material insider reductions by the CEO often trigger investor concern about insider conviction and can add selling pressure. Read More.
• Negative Sentiment: Other senior insiders (COO Jeffrey Nelson, and executives David Bharucha and Lorenz Muller) also sold large blocks on Dec. 15 and Jan. 26, representing double‑digit percentage cuts to their stakes—a clustered pattern that intensifies negative sentiment and helps explain downward pressure on the share price. Read More. Read More. Read More.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. TD Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Wells Fargo & Company increased their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Finally, Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Institutional Trading of Milestone Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning increased its position in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after purchasing an additional 10,000 shares during the last quarter. Raymond James Financial Inc. lifted its position in Milestone Pharmaceuticals by 30.1% in the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after buying an additional 10,000 shares during the last quarter. Bay Rivers Group increased its position in shares of Milestone Pharmaceuticals by 72.9% during the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock valued at $58,000 after acquiring an additional 12,170 shares during the last quarter. Sapient Capital LLC purchased a new position in shares of Milestone Pharmaceuticals during the 3rd quarter worth approximately $25,000. Finally, Bank of America Corp DE lifted its stake in Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares in the last quarter. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.